Clinical aspects of the use of insulin glargine (300 ED/ml) in patients with type 2 diabetes: from research to outpatient practice

• Alexander S. Ametov
• Anna O. Nevolnikova
• Mishra O.A.
• Golubeva L.B.

Abstract

Insulin therapy for type 2 diabetes has a special impotance. Achievement of glycemic targets with the timely appointment of insulin not only reduces the risk of micro- and macrovascular complications of this pathology, but also contributes to the preservation of the secretory reserve of pancreatic β-cells by eliminat­ing glucose toxicity. The leading role in the formation of a stable glycemic background belongs to basal insu­lin as a prototype of basal secretion of insulin. Despite the obvious advantages of the already existing basal insulin analogues, when they are used, many patients with type 2 diabetes continue to experience hypoglyce­mia, increased appetite, and, as a consequence, weight gain. The article presents a clinical analysis of the use of insulin glargine at a concentration of 300 U/ml (glargine U-300) in 144 patients with type 2 diabetes in a routine outpatient setting. The features and points of control are described in detail in various clinical situ­ations: when initiating insulin therapy, transferring to glargine U-300, which will allow using the new basal insulin preparation with maximum efficiency.

Keywords:diabetes mellitus type 2, basal insulin preparations, practical application, clinical features, glucose toxicity, initiation of insulin therapy, NPH-insulin, Lantus, Toujeo, glargine U-300, glargine U-100

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)